主要作者

　　摘要标题

　　演示文稿详情(CDT)

　　抗体偶联药物

　　Shitara, K

　　Trastuzumab deruxtecan (T-
DXd) vs ramucirumab (RAM) +
paclitaxel (PTX) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (HER2+)
unresectable/metastatic gastric
cancer (GC) or
gastroesophageal junction
adenocarcinoma (GEJA):
Primary analysis of the
randomized, phase 3
DESTINY-Gastric04 study.

　　Abstract #LBA4002

　　Oral Abstract Session

　　31 May 2025

　　3:24pm

　　Tolaney, SM

　　Trastuzumab deruxtecan (T-
DXd) + pertuzumab (P) vs
taxane + trastuzumab +
pertuzumab (THP) for first-line
(1L) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(HER2+) advanced/metastatic
breast cancer (a/mBC): Interim
results from DESTINY-Breast09.

　　Abstract #LBA1008

　　Oral Abstract Session

　　2 June 2025

　　7:30am

　　Dent, R

　　Exploratory biomarker analysis
of trastuzumab deruxtecan (T-
DXd) vs physician's choice of
chemotherapy (TPC) in HER2-
low/-ultralow, hormone
receptor-positive (HR+)
metastatic breast cancer (mBC)
in DESTINY-Breast06 (DB-06).

　　Abstract #1013

　　Oral Abstract Session

　　31 May 2025

　　3:23pm

　　Levy, BP

　　TROPION-Lung02:
Datopotamab deruxtecan
(Dato-DXd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (Pt-CT) as first-
line (1L) therapy for advanced
non-small cell lung cancer (aNSCLC).

　　Abstract #8501

　　Oral Abstract Session

　　1 June 2025

　　8:12am

　　Waqar, SN

　　First-line (1L) datopotamab
deruxtecan (Dato-DXd) +
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mNSCLC): Results
from TROPION-Lung04 (cohort 5).

　　Abstract #8521 

　　Poster Session

　　31 May 2025

　　1:30pm

　　肿瘤驱动因素和耐药性

　　Turner, NC

　　Camizestrant + CDK4/6
inhibitor (CDK4/6i) for the
treatment of emergent ESR1
mutations during first-line (1L)
endocrine-based therapy (ET)
and ahead of disease
progression in patients (pts)
with HR+/HER2– advanced
breast cancer (ABC): Phase 3,
double-blind ctDNA-guided
SERENA-6 trial.

　　Abstract #LBA4

　　Plenary Session

　　1 June 2025

　　2:41pm

　　Lu, S

　　Savolitinib (Savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
EGFR-mutant (EGFRm) and
MET-amplification (METamp)
advanced NSCLC after disease
progression (PD) on EGFR
tyrosine kinase inhibitor (TKI):
Results from a randomized
phase 3 SACHI study.

　　Abstract #LBA8505

　　Oral Abstract Session

　　1 June 2025

　　9:48am

　　Levy, BP

　　Efficacy and CNS results from
a randomized subset of the
phase 2 SAVANNAH study
comparing savolitinib (savo) +
osimertinib (osi) combination
with savo + placebo (PBO).

　　Abstract #8513

　　Rapid Oral Abstract Session

　　2 June 2025

　　8:06am

　　Chaft JE

　　Neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (CT) vs CT
alone in resectable (R)
epidermal growth factor
receptor-mutated (EGFRm)
NSCLC: NeoADAURA.

　　Abstract #8001

　　Oral Abstract Session

　　2 June 2025

　　3:12pm

　　免疫肿瘤学与双特异性抗体

　　Janjigian, YY

　　Event-free survival in
MATTERHORN: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (FLOT) in
resectable
gastric/gastroesophageal
junction cancer (GC/GEJC).

　　Abstract #LBA5

　　Plenary Session

　　1 June 2025

　　3:13pm

　　Powles, T

　　Circulating tumor DNA (ctDNA)
in patients with muscle-invasive
bladder cancer (MIBC) who
received perioperative
durvalumab (D) in NIAGARA

　　Abstract #4503

　　Oral Abstract Session

　　1 June 2025

　　10:45am

　　Reck, M

　　Associations of post-surgical
MRD status with neoadjuvant
ctDNA dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable NSCLC (R-NSCLC)
from the phase 3 AEGEAN trial.

　　Abstract #8009

　　Rapid Oral Abstract Session

　　1 June 2025

　　4:30pm

　　Barbie, DA

　　Clinical and molecular
characteristics of early
progressors (EPs) and long
-term progression-free survivors
(LTPs) from the phase 3
ADRIATIC trial of
consolidation durvalumab (D) vs placebo (P)
after concurrent
chemoradiotherapy (cCRT) in
limited-stage small-cell lung
cancer (LS-SCLC).

　　Abstract #8014

　　Rapid Oral Abstract Session

　　1 June 2025

　　5:12pm

　　Mayadev, J

　　Ultrasensitive detection and
tracking of circulating tumor
DNA (ctDNA) and association
with relapse and survival in
locally advanced cervical
cancer (LACC): Phase 3
CALLA trial analyses.

　　Abstract #5502

　　Oral Abstract Session

　　2 June 2025

　　8:48am

　　Westin, SN

　　Durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
Longitudinal changes in
circulating tumor DNA.

　　Abstract #5512

　　Rapid Oral Abstract Session

　　3 June 2025

　　8:30am

　　Erinjeri, JP

　　Outcomes by baseline tumor
burden using the 6-and-12
score in EMERALD-1: a phase
3 study of durvalumab (D) ±
bevacizumab (B) with transarterial
chemoembolization (TACE) in
embolization-eligible
unresectable hepatocellular
carcinoma (uHCC).

　　Abstract #4083
Poster Session

　　31 May 2025

　　9:00am

　　Cascone, T

　　Neoadjuvant durvalumab (D) +
chemotherapy (CT) + novel
anticancer agents and adjuvant
D ± novel agents in resectable
non-small-cell lung cancer
(NSCLC): Updated outcomes
from NeoCOAST-2.

　　Abstract #8046

　　Poster Session

　　31 May 2025

　　1:30pm

　　Zhou, J

　　First-line rilvegostomig (rilve)
plus chemotherapy (CTx) in
advanced biliary tract cancer
(BTC): Primary analysis of
GEMINI-Hepatobiliary substudy
2 Cohort A.

　　Abstract #4080

　　Poster Session

　　31 May 2025

　　9:00am

　　Xu, R

　　ARTEMIDE-Gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (T-
DXd) as first-line (1L) treatment
for locally advanced or
metastatic HER2-positive
gastric or gastroesophageal
junction cancer (GC/GEJC).

　　Abstract #TPS4204

　　Poster Session

　　31 May 2025

　　9:00am

　　Mathias, C

　　ARTEMIDE-Lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express PD-L1.

　　Abstract #TPS8653

　　Poster Session

　　31 May 2025

　　1:30pm

　　细胞疗法

　　Yoo, C

　　RHEA-1: First-in-human (FIH)
study of AZD9793, a first-in-
class CD8-guided T cell-
engager (TCE) for glypican-3-
positive (GPC3+) advanced or
metastatic hepatocellular
carcinoma (HCC).

　　Abstract #TPS4215

　　Poster Session

　　31 May 2025

　　9:00am

　　Kim, TM

　　Safety and Efficacy of
AZD0486, a CD19xCD3 T-cell
Engager, in Relapsed or
Refractory Diffuse Large B-cell
Lymphoma.

　　Abstract #7046
Poster Session

　　1 June 2025

　　9:00am

　　Shadman, M

　　TITANium: An open-label,
global multicenter Phase 1/2
study of AZD5492, a first-in-
class subcutaneous CD8-
guided tri-specific T-cell
engager (TCE), in patients (pts)
with relapsed or refractory (r/r)
B-cell malignancies.

　　Abstract #TPS7091

　　Poster Session

　　1 June 2025

　　9:00am

　　Le Gouill, S

　　SOUNDTRACK-E: A Phase 1/2
Open-label Multicenter Study to
Evaluate the Safety and
Efficacy of AZD0486
Monotherapy or Combination
Therapy in Patients With
Mature B-cell Malignancies.

　　Abstract #TPS7083

　　Poster Session

　　1 June 2025

　　9:00am

　　罕见病药物

　　Chen, AP

　　Efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (NF1)
and symptomatic, inoperable
plexiform neurofibroma (PN):
Primary analysis of KOMET
(NCT04924608), a Phase 3,
international, randomized,
placebo-controlled study.

　　Abstract #3014

　　Rapid Oral Abstract Session

　　2 June 2025

　　8:00am

　　1阿斯利康在2025年ASCO大会将公布超过80个摘要，涵盖其产品和管线中的分子药物